A Phase 1 interventional study of AZD5004 and Placebo in Obesity or Overweight and Type 2 Diabetes, sponsored by Eccogene. Completed at 6 sites in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Eccogene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 601 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.
Among the 601 studies in Obesity with a site in China, this one is the 406th largest by enrollment of the 503 interventional ones that give a count, is one of 114 that started in 2025, is one of 93 in phase 1, and was the 364th registered.
11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.
Browse Obesity studies →221 of the 601 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
601 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 103 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 114 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 67 across 9,027 interventional studies indexed under Obesity.
Median enrollment 120 across the 503 interventional studies, 310 across the 98 observational. Of the 242 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
241 of 601 have an industry lead sponsor. The 10 most frequent:
Eccogene is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Eccogene has 2 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
104 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Add all 104 to your calendar (.ics) → With an account.
Among the 601 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese participants with overweight/obesity with or without T2DM.
This is a Phase Ib, randomized, parallel-group, double-blind, placebo-controlled, multicentre, 2-arm treatment study to investigate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese male and female participants aged 18 to 74 years, who are overweight/obese with or without T2DM. The primary endpoints are incidence of AEs, SAEs, DAEs, death, AESIs, laboratory parameters, 12-lead ECG, and vital signs.
Inclusion Criteria:
Inclusion Criteria for Cohort A:
- 27 kg/m2 ≤ ≤ 35 kg/m2 and weigh at least 60 kg at Screening.
Inclusion Criteria for Cohort B:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive AZD5004 orally.
Drug: AZD5004
Participants will receive Placebo orally.
Drug: Placebo
AZD5004 will be administered as an oral tablet once daily.
Placebo will be administered as an oral tablet once daily.
Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse event leading to the discontinuation of study intervention (DAEs), death, and Adverse events of special interest (AESIs)
To evaluate the safety and tolerability of AZD5004 compared with placebo.
Time frame: From baseline to week 16.
AZD5004 concentrations in plasma
To characterize the PK profile of AZD5004 following repeated administration.
Time frame: Week 16.
Area under the concentration-time curve over a dosing interval (AUCtau)
To characterize the PK profile of AZD5004 following repeated administration.
Time frame: Week 16.
Maximum Observed Plasma Concentration (Cmax)
To characterize the PK profile of AZD5004 following repeated administration.
Time frame: Week 16.
Half-Life (t1/2)
To characterize the PK profile of AZD5004 following repeated administration.
Time frame: Week 16.
Time of Occurrence of Maximum Plasma Concentration (tmax)
To characterize the PK profile of AZD5004 following repeated administration.
Time frame: Week 16.
Trough concentration (Ctrough)
To characterize the PK profile of AZD5004 following repeated administration.
Time frame: Week 16.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Nov 2025, 5 months.
Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 5 months is below that.
Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elecoglipron
Eccogene